KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Raw Materials (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Raw Materials for 14 consecutive years, with $188.5 million as the latest value for Q2 2022.

  • On a quarterly basis, Raw Materials rose 56.87% to $188.5 million in Q2 2022 year-over-year; TTM through Jun 2022 was $188.5 million, a 56.87% increase, with the full-year FY2021 number at $116.9 million, down 7.9% from a year prior.
  • Raw Materials was $188.5 million for Q2 2022 at Bio-Rad Laboratories, up from $146.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $188.5 million in Q2 2022 to a low of $104.0 million in Q1 2020.
  • A 5-year average of $123.3 million and a median of $118.3 million in 2018 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: dropped 18.41% in 2021, then soared 56.87% in 2022.
  • Bio-Rad Laboratories' Raw Materials stood at $108.0 million in 2018, then increased by 1.45% to $109.6 million in 2019, then increased by 15.83% to $126.9 million in 2020, then decreased by 7.9% to $116.9 million in 2021, then surged by 61.26% to $188.5 million in 2022.
  • Per Business Quant, the three most recent readings for BIO's Raw Materials are $188.5 million (Q2 2022), $146.2 million (Q1 2022), and $116.9 million (Q4 2021).